Scientists have raised questions about the dataset published in The Lancet last week that triggered the suspension of clinical trials around the world—and about Surgisphere Corporation, the company behind the study.

Coronavirus experts are swamped with reading submissions, which they’re working through as quickly as possible.

When submitting manuscripts to Western journals, authors face issues that go beyond language barriers.

Nearly 100 academic journals, societies, institutes, and companies sign a commitment to make research and data on COVID-19 freely available, at least for the duration of the outbreak.

Scientists see great value in catchy acronyms, so they get creative when it comes to naming new tools and techniques.

Constructively critiquing the scientific literature should be an essential part of the postdoctoral experience, and early career researchers have shown that they are up to the task.

Last month, 10 UK universities became part of the UK Reproducibility Network, joining researchers, funders, journal publishers, and regulatory agencies.

Publishers’ efforts to reduce “leakage,” funder-driven open-access schemes, the growth of academic publishing in China, and more.

Licensing negotiations between libraries and publishers continued, a radical open-access plan made changes, and the flaws of some publishing tools and techniques came to light.